XOMA CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.98 USD | +1.07% |
|
+5.45% | +35.03% |
| May. 09 | Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M | MT |
| May. 09 | XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Thank you for joining XOMA Corporation's 2021 ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
24.71
USD
Average target price
58
USD
Spread / Average Target
+134.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.03% | 288M | |
| +7.36% | 113B | |
| +11.15% | 106B | |
| +0.44% | 22.27B | |
| -12.03% | 22.22B | |
| -5.99% | 19.43B | |
| -37.85% | 17.87B | |
| -6.25% | 17.24B | |
| +7.07% | 14.29B | |
| +34.84% | 12.52B |
- Stock Market
- Equities
- XOMA Stock
- News XOMA Corporation
- Transcript : XOMA Corporation - Shareholder/Analyst Call